je.st
news
Tag: patients
Tayside patients get access to free wifi in hospitals across the region
2015-10-05 00:11:08| Wireless - Topix.net
NHS patients in Tayside are being given access to free wifi, which has been rolled out in hospitals across the region. Patients at Ninewells, Stracathro and Perth Royal Infirmary can connect to the patient wifi in all wards and treatment areas which have wireless access.
Personalized genetic testing for cancer to reach more than 1 million patients
2015-10-04 05:24:38| IT Services - Topix.net
Authentidate Holding Corp. has partnered with AEON Clinical Laboratories to launch Cancer Detect Profile , a 38-gene cancer genetic test coupled with telehealth-based genetic counseling for 6,000 prescribing physicians throughout the country. The test is designed to identify patients with increased risk of colorectal, breast, pancreatic, ovarian, gastric, melanoma, stomach and other cancers by analyzing mutations in their DNA and RNA within a panel of 38-genes associated with cancer.
Tags: million
reach
testing
cancer
FDA Approves KEYTRUDA (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
2015-10-02 20:49:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Patients with EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression on FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab) monotherapy, the companys anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg every three weeks, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: or
express
cell
treatment
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
2015-10-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & HOUSTON KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrixs oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325Investor Relations:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orDNAtrixInvestor/Media Relations:Imran Alibhai, Ph.D.ialibhai@dnatrix.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
10.02.15 -- Drug Resistance In Cancer Patients Linked To Oxygen-Bearing Molecules In Body
2015-10-01 02:20:33| drugdiscoveryonline Home Page
10/02/15 Drug Discovery Online Newsletter
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »